Biologics are medicinal products manufactured or derived from biological sources such as living organisms or their components. They include vaccines, blood and blood components, allergenics, somatic cells, gene therapy, tissues, and recombinant therapeutic proteins. The wide range of biologics available has revolutionized the treatment of chronic diseases such as cancer, autoimmune disorders, and other genetic conditions. Biologics, when compared to small molecule drugs, have fewer side effects and are able to target specific molecular entities involved in disease pathways.

The global biologics market is estimated to be valued at US$ 463.06 Bn in 2024 and is expected to exhibit a CAGR of 8.2% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.

Market Dynamics:

Increasing Demand for Biologics for Treatment of Chronic Diseases

Rise in chronic diseases such as cancer, diabetes, autoimmune disorders is one of the major drivers of the biologics market. According to the Centers for Disease Control and Prevention, in the U.S. around 133 million Americans were living with at least one chronic disease in 2016. Biologics are highly effective in management of such chronic diseases with high degree of precision and minimal side effects. For instance, biologics such as monoclonal antibodies have revolutionized cancer treatment by precisely targeting tumor microenvironment.

Factors such as approval and launch of new biologics, increasing demand for targeted therapies and rising healthcare expenditures will continue to offer significant opportunities for players in the global biologics market over the forecast period. However, high costs of biologics are expected to hinder market growth.

SWOT Analysis

Strength: The biologics market offers alternative treatment options for various diseases. Biologics such as monoclonal antibodies have revolutionized cancer treatment by precisely targeting tumor cells. Some biologics are cost-effective medicines that help treat chronic conditions like rheumatoid arthritis and decrease long-term healthcare costs.

Weakness: Biologics require complex manufacturing processes and are more expensive to produce than traditional drugs. Their production involves living cells and depends on bioreactors and exact growth conditions for cells. This results in higher costs which are usually not affordable for many patients. Long-term effects of certain biologics are still unknown which limits their widespread usage.

Opportunity: The rising incidence of cancer, autoimmune diseases, and other chronic conditions drives the demand for specialized treatment options. Biologics present a major opportunity to demonstrate efficacy in new therapeutic areas and provide affordable treatment options in developing markets. Increasing focus on value-based healthcare may lower costs and improve access to biologics globally.

Threats: Patent expirations of major biologics allow the entry of biosimilars which threatens the market share of innovator companies. Stringent regulations for manufacturing and approvals also affect the biotechnology industry's ability to innovate and commercialize new products. Healthcare reforms and uncertain funding may restrict access to expensive biologics in certain countries.

Key Takeaways
Global Biologics Market Size is expected to witness high growth in the forecast period of 2024 to 2031 driven by the rising burden of non-communicable diseases. According to market estimates, the biologics industry size will increase from US$ 463.06 billion in 2024 to over US$1 trillion by 2031, registering a CAGR of 8.2%.

Regional analysis: North America currently dominates the biologics market owing to presence of major manufacturers and availability of advanced healthcare facilities. The United States accounts for over 40% of global sales. However, Asia Pacific is emerging as the fastest growing regional market due to growing medical needs of its large population and increasing affordability of biologics in countries like China and India.

Key players: Key players operating in the biologics market are Advanced Accelerator Applications, Seattle Genetics, Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Merck, Novo Nordisk, Sanofi, and Pfizer. These leading companies are focusing on expanding their product portfolios through acquisitions and partnerships to strengthen their presence across major markets.

Get More Insights On This Topic: https://www.trendingwebwire.com/global-biologics-market-propelled-by-growing-demand-for-biosimilars/